



WARNING LETTER

DATE: May 27, 2021

TO: oclo@usa.com – Ricardo Garcia
OCLO LLC
220 SW 9th Ave, #506
Hallandale, FL 33009

RE: Unapproved and Misbranded

Some examples of the previous claims on your websites that established the intended use of your products and misleadingly represented them as safe and/or effective for the treatment or prevention of COVID-19 included:

x “B117...New variant of coronavirus, the most contagious and dangerous in the United States [,] Rescuing Chlorine Dioxide and its great curative potential against pathogens . . . OCLO Nanotechnology Science manufactures different products with chlorine dioxide in aqueous CDS solution, in order to combat numerous viruses and other pathogens, according to protocols established by the German scientist Dr. Andreas Kalcker as a result of his scientific research and extensive experience of (sic)-practices. human clinics.” [from your webpage <https://dioxidodecloro.us>, accessed April 15, 2021]

x “Scientific Results - Efficacy of Chlorine Dioxide

Journal of Molecular Genetics Published March 8, 2021

Determinación de la eficacia del dióxido de cloro en el tratamiento de COVID 19

Conclusion: El dióxido de cloro es eficaz en el tratamiento del COVID19 y en este trabajo se proponen los mecanismos de acción por los que actúa para conseguirlo”

Add 15 to 20 drops of the CDS solution to HALF GLASS of drinking water (120 mL) to obtain a solution of 25 to 30 ppm, a concentration indicated for human consumption safely.” [from your webpage <https://dioxidodecloro.us/products/oclo-3000-dioxido-de-cloro-oral-gotas>, accessed April 15, 2021]

We note that, as of the date of this letter, your internet website <https://dioxidodecloro.us> has been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.

You should take immediate action to address the violations cited in this letter. This letter is

pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to \$43,792 per violation and may be required